Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock

T. Jäntti, T. Tarvasmäki, VP. Harjola, J. Parissis, K. Pulkki, T. Javanainen, H. Tolppanen, R. Jurkko, M. Hongisto, A. Kataja, A. Sionis, J. Silva-Cardoso, M. Banaszewski, J. Spinar, A. Mebazaa, J. Lassus, CardShock investigators,

. 2019 ; 14 (5) : e0217006. [pub] 20190516

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006358

INTRODUCTION: The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and their effects on mortality in cardiogenic shock are unknown. MATERIALS AND METHODS: P-Alb was measured from serial blood samples in 178 patients from a prospective multinational study on cardiogenic shock. The association of hypoalbuminemia with clinical characteristics and course of hospital stay including treatment and procedures was assessed. The primary outcome was all-cause 90-day mortality. RESULTS: Hypoalbuminemia (P-Alb < 34g/L) was very frequent (75%) at baseline in patients with cardiogenic shock. Patients with hypoalbuminemia had higher mortality than patients with normal albumin levels (48% vs. 23%, p = 0.004). Odds ratio for death at 90 days was 2.4 [95% CI 1.5-4.1] per 10 g/L decrease in baseline P-Alb. The association with increased mortality remained independent in regression models adjusted for clinical risk scores developed for cardiogenic shock (CardShock score adjusted odds ratio 2.0 [95% CI 1.1-3.8], IABP-SHOCK II score adjusted odds ratio 2.5 [95%CI 1.2-5.0]) and variables associated with hypoalbuminemia at baseline (adjusted odds ratio 2.9 [95%CI 1.2-7.1]). In serial measurements, albumin levels decreased at a similar rate between 0h and 72h in both survivors and nonsurvivors (ΔP-Alb -4.6 g/L vs. 5.4 g/L, p = 0.5). While the decrease was higher for patients with normal P-Alb at baseline (p<0.001 compared to patients with hypoalbuminemia at baseline), the rate of albumin decrease was not associated with outcome. CONCLUSIONS: Hypoalbuminemia was a frequent finding early in cardiogenic shock, and P-Alb levels decreased during hospital stay. Low P-Alb at baseline was associated with mortality independently of other previously described risk factors. Thus, plasma albumin measurement should be part of the initial evaluation in patients with cardiogenic shock. TRIAL REGISTRATION: NCT01374867 at ClinicalTrials.gov.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006358
003      
CZ-PrNML
005      
20200518132555.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0217006 $2 doi
035    __
$a (PubMed)31095609
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jäntti, Toni $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
245    10
$a Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock / $c T. Jäntti, T. Tarvasmäki, VP. Harjola, J. Parissis, K. Pulkki, T. Javanainen, H. Tolppanen, R. Jurkko, M. Hongisto, A. Kataja, A. Sionis, J. Silva-Cardoso, M. Banaszewski, J. Spinar, A. Mebazaa, J. Lassus, CardShock investigators,
520    9_
$a INTRODUCTION: The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and their effects on mortality in cardiogenic shock are unknown. MATERIALS AND METHODS: P-Alb was measured from serial blood samples in 178 patients from a prospective multinational study on cardiogenic shock. The association of hypoalbuminemia with clinical characteristics and course of hospital stay including treatment and procedures was assessed. The primary outcome was all-cause 90-day mortality. RESULTS: Hypoalbuminemia (P-Alb < 34g/L) was very frequent (75%) at baseline in patients with cardiogenic shock. Patients with hypoalbuminemia had higher mortality than patients with normal albumin levels (48% vs. 23%, p = 0.004). Odds ratio for death at 90 days was 2.4 [95% CI 1.5-4.1] per 10 g/L decrease in baseline P-Alb. The association with increased mortality remained independent in regression models adjusted for clinical risk scores developed for cardiogenic shock (CardShock score adjusted odds ratio 2.0 [95% CI 1.1-3.8], IABP-SHOCK II score adjusted odds ratio 2.5 [95%CI 1.2-5.0]) and variables associated with hypoalbuminemia at baseline (adjusted odds ratio 2.9 [95%CI 1.2-7.1]). In serial measurements, albumin levels decreased at a similar rate between 0h and 72h in both survivors and nonsurvivors (ΔP-Alb -4.6 g/L vs. 5.4 g/L, p = 0.5). While the decrease was higher for patients with normal P-Alb at baseline (p<0.001 compared to patients with hypoalbuminemia at baseline), the rate of albumin decrease was not associated with outcome. CONCLUSIONS: Hypoalbuminemia was a frequent finding early in cardiogenic shock, and P-Alb levels decreased during hospital stay. Low P-Alb at baseline was associated with mortality independently of other previously described risk factors. Thus, plasma albumin measurement should be part of the initial evaluation in patients with cardiogenic shock. TRIAL REGISTRATION: NCT01374867 at ClinicalTrials.gov.
650    _2
$a senioři $7 D000368
650    _2
$a příčina smrti $7 D002423
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mortalita v nemocnicích $7 D017052
650    _2
$a lidé $7 D006801
650    _2
$a hypoalbuminemie $x krev $x komplikace $x mortalita $7 D034141
650    _2
$a délka pobytu $7 D007902
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a odds ratio $7 D016017
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a kardiogenní šok $x krev $x komplikace $x mortalita $7 D012770
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tarvasmäki, Tuukka $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Harjola, Veli-Pekka $u Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Parissis, John $u Heart Failure Clinic and Secondary Cardiology Department, Attikon University Hospital, Athens, Greece.
700    1_
$a Pulkki, Kari $u Laboratory Division, Turku University Hospital and Department of Clinical Chemistry, University of Turku, Turku, Finland.
700    1_
$a Javanainen, Tuija $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Tolppanen, Heli $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Jurkko, Raija $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Hongisto, Mari $u Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Kataja, Anu $u Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Sionis, Alessandro $u Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-SantPau, Universidad Autónoma de Barcelona, Barcelona, Spain.
700    1_
$a Silva-Cardoso, Jose $u Department of Cardiology, CINTESIS, Porto Medical School, São João Hospital Center, University of Porto, Porto, Portugal.
700    1_
$a Banaszewski, Marek $u Intensive Cardiac Therapy Clinic, Institute of Cardiology, Warsaw, Poland.
700    1_
$a Spinar, Jindrich $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Mebazaa, Alexandre $u INSERM U942, University Paris Diderot and Department of Anesthesia and Critical Care, Hôpital Lariboisière, APHP, Paris, France.
700    1_
$a Lassus, Johan $u Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
710    2_
$a CardShock investigators
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 14, č. 5 (2019), s. e0217006
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31095609 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518132554 $b ABA008
999    __
$a ok $b bmc $g 1525216 $s 1096414
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 5 $d e0217006 $e 20190516 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...